Clínica Universidad de Navarra (CUN)
Centro clínico de la Universidad de Navarra
Medical College of Wisconsin
Milwaukee, Estados UnidosPublications en collaboration avec des chercheurs de Medical College of Wisconsin (41)
2024
-
Clinical and biological landscape of constitutional mismatch-repair deficiency syndrome: an International Replication Repair Deficiency Consortium cohort study
The Lancet Oncology, Vol. 25, Núm. 5, pp. 668-682
-
Hacia la estandarización de la formación de PoCUS en nefrología: el momento es ahora
Nefrologia, Vol. 44, Núm. 1, pp. 5-9
-
Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA/ENGOT-OV26/GOG-3012 trial
Annals of Oncology
-
Plain language summary of the CARTITUDE-4 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma
Future Oncology
-
Stroke in critically ill patients with respiratory failure due to COVID-19: Disparities between low-middle and high-income countries
Heart and Lung, Vol. 68, pp. 131-144
2023
-
Advanced MR Techniques for Preoperative Glioma Characterization: Part 1
Journal of Magnetic Resonance Imaging, Vol. 57, Núm. 6, pp. 1655-1675
-
Advanced MR Techniques for Preoperative Glioma Characterization: Part 2
Journal of Magnetic Resonance Imaging, Vol. 57, Núm. 6, pp. 1676-1695
-
Antithrombotic management of patients with deep vein thrombosis and venous stents: an international registry
Journal of Thrombosis and Haemostasis, Vol. 21, Núm. 12, pp. 3581-3588
-
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
New England Journal of Medicine, Vol. 389, Núm. 4, pp. 335-347
-
Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)
Leukemia
-
Outcomes of Infants and Young Children With Relapsed Medulloblastoma After Initial Craniospinal Irradiation Sparing Approaches: An International Cohort Study
Journal of Clinical Oncology, Vol. 41, Núm. 10, pp. 1921-1932
-
Overall Survival with Maintenance Olaparib at a 7-Year Follow-Up in Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
Journal of Clinical Oncology, Vol. 41, Núm. 3, pp. 609-617
-
Overall Survival with Maintenance Olaparib at a 7-Year Follow-up in Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
Obstetrical and Gynecological Survey
2022
-
ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Multiple Myeloma
Transplantation and Cellular Therapy, Vol. 28, Núm. 6, pp. 284-293
-
Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study
Gynecologic Oncology, Vol. 166, Núm. 1, pp. 36-43
-
Variations in management of A3 and A4 cervical spine fractures as designated by the AO Spine Subaxial Injury Classification System
Journal of Neurosurgery: Spine, Vol. 36, Núm. 1, pp. 99-112
2021
-
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1
Autophagy, Vol. 17, Núm. 1, pp. 1-382
-
International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials
Leukemia, Vol. 35, Núm. 1, pp. 18-30
-
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial
The Lancet Oncology, Vol. 22, Núm. 12, pp. 1721-1731
-
Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial
The Lancet Oncology, Vol. 22, Núm. 5, pp. 632-642